文献速递药物不良反应与药物警戒肝肾功能剂量调整治疗药物监测与药物基因组学

儿童中万古霉素联用哌拉西林-他唑巴坦与急性肾损伤频率的研究

Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
PubMed 文献 · Am J Health Syst Pharm · 2019-01-01

本研究为单中心回顾性队列研究,纳入474例接受至少48小时联合治疗且有基线及随访血肌酐和万古霉素谷浓度的儿科患者,比较万古霉素联合哌拉西林-他唑巴坦与联合其他抗假单胞菌β-内酰胺类药物的急性肾损伤(AKI)频率。结果显示联合哌拉西林-他唑巴坦组AKI发生率更高(27% vs 7%),且AKI发生时间更早。

要点

  • 儿童联用万古霉素与哌拉西林-他唑巴坦的AKI发生率显著高于联用其他抗假单胞菌β-内酰胺类药物。
  • 联用哌拉西林-他唑巴坦患者发生AKI的风险约为联用其他药物的6倍。
  • 万古霉素谷浓度大于20 mg/L的患者发生AKI的风险约为7.5倍。

核心结论

  • 儿科患者联用万古霉素与哌拉西林-他唑巴坦相比联用其他抗假单胞菌β-内酰胺类药物,AKI发生率更高且发生时间更早。

研究设计与样本

  • 回顾性单中心队列研究,纳入474例接受至少48小时联合治疗、有基线及随访血肌酐和万古霉素谷浓度记录的儿科患者。

主要发现

  • 万古霉素联合哌拉西林-他唑巴坦组(100例)AKI发生率为27%,高于联合其他抗假单胞菌β-内酰胺类药物组的7%(p < 0.0001)。
  • 哌拉西林-他唑巴坦组AKI发生中位时间短于其他药物组(3.8天 vs 7.9天,p = 0.0065)。
  • 使用哌拉西林-他唑巴坦患者发生AKI的比值比为5.955(95% CI 2.774-12.784)。
  • 万古霉素最大谷浓度大于20 mg/L患者发生AKI的比值比为7.552(95% CI 3.625-15.734)。

关键数值与推荐

  • AKI定义为血肌酐较基线升高≥50%或较基线升高至少0.5 mg/dL。

临床怎么用

  • 儿科患者联用万古霉素与哌拉西林-他唑巴坦时应密切监测肾功能,尤其关注万古霉素谷浓度大于20 mg/L的情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Results of a study of rates of acute kidney injury (AKI) in pediatric patients treated with vancomycin plus piperacillin-tazobactam or vancomycin plus alternative antipseudomonal β-lactams (APBLs) are reported. METHODS: A retrospective, single-center cohort study was performed. Pediatric patients were included in the study cohort if they received combination therapy for at least 48 hours, had documented baseline and follow-up serum creatinine levels, and had a documented serum vancomycin trough concentration. The primary outcome was the frequency of AKI, defined as a 50% or greater increase in serum creatinine concentration from baseline or an increase of at least 0.5 mg/dL from baseline. The secondary outcome was time to AKI onset. RESULTS: A total of 474 patients were included. Among 100 patients who received vancomycin plus piperacillin-tazobactam, the rate of AKI was higher than the rate in the group treated with vancomycin plus alternative APBLs (27% versus 7%, p < 0.0001). The median time to AKI onset was shorter in the piperacillin-tazobactam group versus the alternative APBL group (3.8 versus 7.9 days, p = 0.0065). Patients who were administered piperacillin-tazobactam were almost 6 times as likely to develop AKI (odds ratio [OR], 5.955; 95% confidence interval [CI], 2.774-12.784), and patients who had a maximum vancomycin trough concentration greater than 20 mg/L were 7.5 times as likely to develop AKI (OR, 7.552; 95% CI, 3.625-15.734). CONCLUSION: Pediatric patients treated with concomitant vancomycin and piperacillin-tazobactam had a higher rate of AKI, with faster AKI onset, than those who received vancomycin in combination with other APBLs.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Buhlinger KM, Fuller KA, Faircloth CB, et al. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients. Am J Health Syst Pharm. 2019. PMID: 31369115. doi:10.1093/ajhp/zxz125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。